Healthcare stocks delivered a strong performance on Wednesday, October 7, showing resilience as broader U.S. markets pulled back. Moderna gained about 5% and Eli Lilly advanced nearly 3%, while the S&P 500 fell 0.22% and the Dow Jones Industrial Average declined 0.66%, as rising Treasury yields and renewed concerns about inflation and higher debt weighed on sentiment.

Healthcare Outperforms as Broader Markets Decline

Moderna and Eli Lilly were among the strongest performers in the S&P 500 during the session. Other major pharmaceutical companies, including Amgen and Johnson & Johnson, also advanced, while CVS Health, the parent company of Aetna, gained ground. The industrial sector recorded the steepest decline among the 11 S&P 500 sectors, underscoring the relative strength of healthcare stocks.

The sector has benefited from several structural themes during 2026. Investors continue to focus on medical innovation, the potential applications of AI and demographic trends that could increase demand for healthcare services. The strength of large pharmaceutical companies has also given the sector defensive characteristics at a time when other areas of the market remain more sensitive to higher financing costs.

Eli Lilly Gains as Weight-Loss Drugs Remain in Focus

One of the key catalysts for Eli Lilly was an updated assessment from Morgan Stanley. The investment bank raised its price target for the company to $1,430 from $1,419, citing expectations for strong sales of its weight-loss medicines. Morgan Stanley also maintained a positive view of Johnson & Johnson, Merck and AbbVie.

The focus on weight-loss drugs highlights how specific growth drivers can continue to support pharmaceutical valuations even as the macroeconomic environment becomes more challenging. Morgan Stanley also pointed to continued merger and acquisition activity across the sector as a potential source of support for healthcare companies. The bank expects the November midterm elections in the U.S. to have a limited impact on healthcare policy.

Treasury Yields and Earnings Season Take Center Stage

The broader market decline was partly driven by higher long-term Treasury yields. The yield on the 30-year U.S. Treasury bond reached a 24-year high, while oil prices remained above $100 a barrel, bringing inflation concerns and the prospect of higher interest rates for longer back into focus.

Attention is now shifting toward third-quarter earnings. UnitedHealth and Johnson & Johnson are scheduled to report results before the market opens next Tuesday, followed by additional healthcare companies. Their results could provide an important test of whether the sector’s recent gains are being supported by improving financial performance and guidance or by investors’ preference for healthcare stocks during a period of market uncertainty.

Going forward, healthcare performance will depend on a combination of corporate earnings, sales expectations for key medicines and developments in healthcare policy. Treasury yields, energy prices and expectations for the Federal Reserve will also remain important factors in equity valuations. Strong earnings and guidance could reinforce the sector’s relative strength, while renewed pressure from higher yields or weaker forecasts could test its resilience.